NCT03110640 - Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2016

Primary Completion Date

June 30, 2020

Study Completion Date

September 30, 2021

Conditions

B-cell Adult Acute Lymphoblastic LeukemiaB-cell Chronic Lymphocytic LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionHematopoietic/Lymphoid CancerRefractory Chronic Lymphocytic Leukemia

Interventions

BIOLOGICAL

anti-CD19 CAR-T

Ex vivo-expanded autologous T cells modified to express CD19 CAR

DRUG

Fludarabine

Patients were given cyclophosphamide 500mg/m2/day on day -4 and fludarabine at 25 mg/m2/day on day -4, day -3, and day -2.

DRUG

Cyclophosphamide

Patients were given cyclophosphamide 500mg/m2/day on day -4.

Trial Locations (1)

325000

RECRUITING

The First Affilicated Hospital of Wenzhou Medical University, Wenzhou